Latest market price
3.83
-0.20-4.96%
OverviewShort InterestFilings
RXRXQT37Recursion Pharmaceuticals, Inc.·NASDAQ
3.83-4.96%
Filing
Down 5.0% — Filed an 8-K material-event report (2026-11-02) — details in the filing.
Medium confidence
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
NAMS-2.49%$19.56BHVN-1.69%$15.16CLDX-3.52%$29.04IMNM+7.58%$19.59RCUS-1.87%$17.85PHVS+0.00%$33.53HRMY-2.19%$37.91XNCR-0.54%$29.66
Snapshot
Index—P/E—EPS (ttm)-1.04Insider Own4.00%Shs Outstand596.88MPerf Week0.79%
Market Cap2.29BForward P/E—EPS next Y-0.87Insider Trans-1.71%Shs Float520.24MPerf Month-7.04%
Enterprise Value1.78BPEG—EPS next Q—Short Float31.13%Perf Quarter15.71%
Income-519.00MP/S41.56EPS this Y—Short Ratio7.64Perf Half Y8.81%
Sales55.00MP/B2.50EPS next Y—ROA-42.79%Short Interest161.93MPerf YTD-6.36%
Book/sh1.53P/C4.19EPS next 5Y—ROE-50.41%52W High5.76 -33.51%Perf Year-32.21%
Cash/sh0.91P/FCF—EPS past 3/5Y—ROIC-48.34%52W Low2.77 38.27%Perf 3Y-30.99%
Dividend Est.—EV/EBITDA—Sales past 3/5Y23.31% 90.37%Gross Margin-46.66%Volatility9.71% 10.33%Perf 5Y-79.03%
Dividend TTM—EV/Sales32.35EPS Y/Y TTM—Oper. Margin-991.72%ATR (14)0.36Perf 10Y—
Dividend Ex-Date—Quick Ratio5.03Sales Y/Y TTM-15.38%Profit Margin-945.92%RSI (14)48.86Recom2.60
Dividend Gr. 3/5Y—Current Ratio5.03EPS Q/Q38.89%SMA20-2.94%Beta1.17Target Price5.90
Payout0.00%Debt/Eq0.04Sales Q/Q-57.89%SMA502.08%Rel Volume1.01Prev Close4.03
Employees600LT Debt/Eq0.04EarningsMar 03SMA2008.71%Avg Volume22.31MPrice3.83
IPO DateApr 16, 2021Option/ShortYes / YesEPS/Sales Surpr.-0.45% —Net Debt/EBITDA—Volume22,444,255Change-4.96%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-16-26ReiteratedMorgan StanleyEqual Weight$5.30 → $5.90
Aug-17-26ReiteratedMorgan StanleyEqual Weight$5.50 → $5.30
May-14-26ReiteratedMorgan StanleyEqual Weight$11 → $5.50
Dec-17-25ReiteratedUBS$11
Dec-17-25ReiteratedMorgan StanleyEqual Weight$11
Dec-17-25UpgradeJP MorganNeutral → Overweight
Feb-28-25ReiteratedLeerink PartnersMarket Perform$6.00
Sep-04-24ReiteratedNeedhamBuy$11
Sep-03-24ReiteratedKeyBancOverweight$12
Sep-03-24ReiteratedJefferiesHold$6.00
Latest News· Times ET
Nov-02-26
Nov-02-2608:11PM
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimateszacks.com
04:30PM
Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chairglobenewswire.com
04:25PM
New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polypsglobenewswire.com
04:05PM
Recursion Appoints Fred Hassan as Chair of the Boardglobenewswire.com
Oct-31-26
Oct-31-2606:45PM
1 Big Winner and 1 Loser From the Upcoming Anthropic IPOfool.com
Oct-30-26
Oct-30-2606:46PM
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investorszacks.com
Oct-29-26
Oct-29-2611:26AM
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?zacks.com
09:00AM
Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings GrowthYahoo
Oct-28-26
Oct-28-2611:01AM
Recursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Releasezacks.com
Oct-27-26
Oct-27-2609:56AM
Why Investors Need to Take Advantage of These 2 Medical Stocks Nowzacks.com
Oct-26-26
Oct-26-2606:50PM
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Considerzacks.com
04:05PM
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3globenewswire.com
Oct-20-26
Oct-20-2606:51PM
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowingzacks.com
Oct-19-26
Oct-19-2608:07AM
Recursion Pharmaceuticals (NASDAQ:RXRX) Given Buy Rating at Needham & Company LLCdefenseworld.net
02:34AM
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price TargetBenzinga
Company

Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue55755944————
Cost of Goods Sold Incl. D&A801214543————
Gross Profit-25-46141————
Selling, General and Administrative Excl. Other153177178111————
Research and Development382425314241————
Other Operating Expense-1701-1————
Operating Income-544-648-479-350————
Interest Expense1220————
Unusual Expense
————————
Non-Operating Income (Expense)2251618————
Net Income Before Taxes-523-645-465-332————
Income Taxes-50-1-4————
Consolidated Net Income-519-645-464-328————
Net Income From Continuing Operations-519-645-464-328————
Net Income-519-645-464-328————
EPS (Recurring)-1.04-1.44-1.69-1.58————
EPS (Basic, Before Extraordinaries)-1.04-1.44-1.69-1.58————
EPS (Diluted)-1.04-1.44-1.69-1.58————
EBITDA-445-559-427-308————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio37.0524.3831.3946.61————
Gross Margin-45.45-61.3323.732.27————
Operating Margin-989.09-864.00-811.86-795.45————
Net Margin-943.64-860.00-786.44-745.45————
Shares Outstanding532447274208————
Market Capitalization2,0381,8281,8522,051————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$7.38$6.10$4.81$3.53$2.25● Close Price0.00M0.49M0.98M1.47M1.96MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Borgeson BlakeDirectorOct 06 '26Sale4.8450,000242,0006,108,287Oct 07
HERSHBERG ROBERTDirectorOct 06 '26Option Exercise2.2225,00055,500187,156Oct 07
HERSHBERG ROBERTDirectorOct 06 '26Sale5.0025,000125,000162,156Oct 07
Khan NajatCEO and PresidentSep 08 '26Sale3.5222,40878,8222,072,890Sep 10
Borgeson BlakeDirectorSep 01 '26Sale3.3430,000100,2006,158,287Sep 02
Borgeson BlakeDirectorAug 04 '26Sale3.2530,00097,5006,188,287Aug 06
Borgeson BlakeDirectorJul 07 '26Sale3.9640,000158,5006,218,287Jul 09
Bumpus NamandjeDirectorJun 18 '26Sale3.183,96312,602127,632Jun 22
Gibson ChristopherDirectorJun 05 '26Sale3.6240,000144,800883,735Jun 05
Khan NajatCEO and PresidentJun 05 '26Sale3.5823,58884,4592,175,796Jun 05
Bumpus NamandjeDirectorJun 03 '26Sale3.544,38615,52643,171Jun 04
Borgeson BlakeDirectorJun 02 '26Sale3.6830,000110,4006,169,863Jun 04
Gibson ChristopherDirectorMay 22 '26Sale3.0840,000123,200883,735May 27
Gibson ChristopherDirectorMay 07 '26Sale3.3740,000134,800926,556May 08
Borgeson BlakeDirectorMay 05 '26Sale3.5230,000105,6006,199,863May 07
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.